7 terminated, 2 active not recruiting, 2 completed, 2 recruiting. 14 Phase 3.
By phase and status
Follow idelalisib: new trials by email Literature Review of idelalisib trials Research Report on idelalisib
Trials (filtered) newest first · largest first
All 14 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) DZD8586, Bendamustine, Idelalisib - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 250 | 2025-09-08 | 2026-06-03 |
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors Tacabrutideg, Bendamustine, Idelalisib - CLL, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 250 | 2025-04-10 | 2026-11-12 |
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies Liso-cel, Idelalisib, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | Withdrawn | | 2024-01-16 | 2024-04-02 |
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Pirtobrutinib, Idelalisib, Bendamustine - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 238 | 2021-03-09 | 2026-04-24 |
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL Acalabrutinib (ACP-196), Rituximab, Idelalisib - Chronic Lymphocytic Leukemia | Phase 3 | Active not recruiting | 310 | 2017-02-02 | 2026-10-23 |
Dose Optimization Study of Idelalisib in Follicular Lymphoma Idelalisib - Follicular Lymphoma | Phase 3 | Terminated | 96 | 2016-01-14 | 2023-08-14 |
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia Idelalisib, Chlorambucil, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | 57 | 2015-04-21 | 2018-11-19 |
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Idelalisib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | 311 | 2014-02-05 | 2018-11-19 |
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Placebo, Rituximab, Idelalisib - Indolent Non-Hodgkin's Lymphomas | Phase 3 | Terminated | 295 | 2013-01-16 | 2018-11-16 |
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Idelalisib, Rituximab, Bendamustine - Indolent Non-Hodgkin's Lymphomas | Phase 3 | Terminated | 475 | 2013-01-02 | 2018-11-16 |
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia Idelalisib, Ofatumumab - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | 261 | 2012-12-04 | 2019-08-14 |
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) Idelalisib - Chronic Lymphocytic Leukemia | Phase 3 | Terminated | 161 | 2012-10-03 | 2019-08-20 |
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) Idelalisib, Rituximab, Bendamustine - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 416 | 2012-06-15 | 2020-03-10 |
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) Idelalisib, Rituximab, Placebo to match idelalisib - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 220 | 2012-04-01 | 2019-05-14 |
Conditions studied
Leukemia, Lymphocytic, Chronic, B-Cell (13) · Lymphoma, Follicular (3) · Leukemia (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Non-Hodgkin (2) · Waldenstrom Macroglobulinemia (2) · Hematologic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1)
Sponsors
Gilead Sciences (9) · Acerta Pharma BV (1) · BeOne Medicines (1) · Dizal Pharmaceuticals (1) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1) · Loxo Oncology, Inc. (1)
Countries
United Kingdom (13) · France (12) · United States (12) · Italy (11) · Australia (10) · Poland (10) · Spain (10) · Canada (9) · Czechia (8) · Germany (8) · Belgium (7) · Hungary (5) · Israel (5) · Russia (5) · South Korea (5)
Top investigators
Marisa Hill, MD (1) · Thomas Jahn, MD (1)
Results publications
PMID 32599655, PMID 24450857, PMID 28257752, PMID 30995176, PMID 31729982, PMID 32459600, PMID 33297794, PMID 33709202, PMID 40479620, PMID 42329537
NIH funding
2015 (2)